DUBLIN, Ireland and TREVOSE, Pa., Oct. 21, 2015 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc (NASDAQ:SBBP) announced today the closing of its initial U.S. public offering of 2,500,000 ordinary shares at a price to the public of $10.00 per ordinary share for aggregate gross proceeds of $25 million, before deducting the underwriting commission and estimated offering expenses. In connection with the offering, Strongbridge Biopharma has granted to the underwriters a 30-day option to purchase up to an additional 375,000 ordinary shares at the public offering price, less the underwriting discount. Strongbridge Biopharma’s ordinary shares are listed on The NASDAQ Global Select Market under the symbol “SBBP”.
Stifel acted as the sole book-running manager for the offering. JMP Securities acted as lead manager, and Roth Capital Partners and Arctic Securities acted as co-managers.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on October 15, 2015. The offering is being made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from: Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Strongbridge Biopharma
Strongbridge Biopharma’s strategic focus is to build a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. Strongbridge Biopharma’s lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing’s syndrome. COR-003 has received orphan designation from both the European Medicines Agency and the U.S. Food and Drug Administration. Strongbridge Biopharma recently expanded its rare endocrine disease franchise with the completion of transactions for two Phase 2 product candidates: COR-004, a novel second-generation antisense compound, which is in clinical development for the treatment of acromegaly and designed to block the synthesis of growth hormone receptor (GHr), thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile, being investigated for the treatment of acromegaly, with potential additional applications in Cushing’s disease and neuroendocrine tumors. Strongbridge Biopharma’s intent is to independently commercialize its rare endocrine assets in key global markets.